Biotech news for Friday, May 15, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Earnings Call Insights: Karyopharm Therapeutics (KPTI) Q1 2026 Management View "Karyopharm continues to execute through an important period for the company with recent and upcoming milestones that we believe can unlock meaningful growth opportunities and shape…
Golden_Brown While President Trump's "Most Favored Nation" policy provides incentives for drugmakers to conduct more of their operations in the US, some biopharmas say it is critical to partner with companies around the world to advance R&D. "We seek innov…
Andy Andrews The strong trend in pharma and biotech dealmaking, which has been ongoing for several years, should continue according to experts. Speaking at the FT US Pharma and Biotech Summit in New York, Eric Tokat, partner at Centerview Partners, noted that…
Corvus Pharmaceuticals ( CRVS ) lost ~13% on Thursday after the biotech posted final data from a Phase 1 trial for its lead candidate, soquelitinib, in patients with atopic dermatitis, an inflammatory skin disorder also known as eczema. Based on Cohorts 3
Earnings Call Insights: Invivyd (IVVD) Q1 2026 Management View "We triggered our DECLARATION study upsizing in early April, and the recruitment speed into this additional upsized cohort occurred well faster than our internal expectations" and "we actually slow…
Earnings Call Insights: Cellectar Biosciences (CLRB) Q1 2026 Management view "The first quarter of 2026 marked a transformational period for Cellectar" and "earlier this month, we reported positive 12-month follow-on data from the Phase IIb CLOVER WaM study" t…
Although President Trump's much-heralded "Most Favored Nation" drug policy promises to bring cheaper medication prices to Americans, it could come at the cost of the US losing its lead in biopharma innovation to China, according to a top executive of the pharm…
Aditxt ( ADTX ) will effect a 1-for-27 reverse split of its common stock, the company said on Thursday. With the opening of trading on May 18, the company’s common stock will trade on a post-split basis under the same symbol ADTX. After the reverse stock split…
Hailshadow/iStock via Getty Images Following a brief trading halt, Regenxbio ( RGNX ) lost ~18% in the premarket on Thursday after the company, alongside its Q1 2026 results, posted late-stage trial data for RGX-202, a gene therapy targeting Duchenne muscular…
Earnings Call Insights: Allogene Therapeutics (ALLO) Q1 2026 Management View "As we move through 2026, next-generation cell therapy is shifting from promise to proof." (CEO David Chang) "In this 24-patient analysis, cema-cel achieved a 58.3% MRD clearance rate…
travellinglight/iStock via Getty Images Biogen ( BIIB ) added ~9% in the premarket on Thursday after the company shared results from a mid-stage trial evaluating diranersen, an experimental therapy for Alzheimer’s disease developed in collaboration with Ionis…